Markets
Business
Investing
Tech
Politics
CNBC TV
Watchlist
Investing Club
PRO

stocks Actavis Inc

  • Warner Chilcott Ltd.'s acne treatment Doryx.
    Actavis to Buy Warner Chilcott for $8.5 Billion

    Generic drugmaker Actavis will buy specialty pharmaceuticals company Warner Chilcott in a stock deal valued at about $8.5 billion.

  • Early Movers: WMT, KSS, CSCO & More

    Some of the names on the move ahead of the open.

  • Actavis Rejects $15 Billion Bid From Mylan: Report

    Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.

  • Early Movers: DIS, DKS, ANF & More

    Some of the names on the move ahead of the open.

  • Merger of Drugmakers Valeant, Actavis on Hold: Source

    A proposed merger of Valeant Pharmaceuticals International Inc and Actavis Inc. was put on hold after the two drugmakers failed to agree on terms of a deal.

  • Early Movers: Insurers, NDAQ, AAPL & More

    Some of the names on the move ahead of the open.

  • High Court Weighs Drug Companies' Generics Policy

    Federal regulators are pressing the Supreme Court to stop big pharmaceuticals from paying generic drug competitors to delay releasing cheaper versions of brand-name drugs.

  • The U.S. Supreme Court building.
    US Supreme Court Will Hear 'Pay for Delay' Drug Case

    The Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market.

  • Watson begins shipping generic diabetes drug

    The Parsippany, N.J.- based company had sued the FDA this summer to gain approval for the drug and sought shared marketing exclusivity for its generic version of the drug. After Watson sued the FDA, the company said Mylan Pharmaceuticals Inc. intervened as a defendant in the action.

  • Mylan at long-time high on outlook, deal talk

    NEW YORK-- Shares of Mylan Inc. rose to their highest price in almost nine years on Friday after the drugmaker reported higher sales of its EpiPen allergy injection and raised its 2012 guidance. The company said it now expects to earn between $2.50 and $2.60 per share in 2012, about 15 cents per share more than it had expected.

  • Watson Pharma climbs as FTC approves Actavis deal

    PARSIPPANY, N.J.-- Shares of Watson Pharmaceuticals Inc. reached new highs Tuesday after the Federal Trade Commission cleared its acquisition of Swiss drugmaker Actavis Group. Watson and Actavis will sell three approved products to Sandoz, a unit of Novartis AG, including generic versions of the antidepressant Wellbutrin XL and the anxiety drug Ativan.

  • BRIEF-Watson's generic Avapro� receives FDA approval

    Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic Avaproï¿ ½ receives FDA approval. *Irbesartan tablets USP is the generic equivalent to Sanofi's Avaproï¿ ½.

  • BRIEF-Watson's Generic Sanctura xr� receives FDA approval

    Oct 12- Watson Pharmaceuticals Inc:. *Watson's generic sanctura xrï¿ ½ receives FDA approval. *Says intends to begin shipping the product immediately.

  • Your First Move for Thursday, Oct. 11

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • EU mergers and takeovers (Oct 8)

    BRUSSELS, Oct 8- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firm Carlyle Group LP to buy photo agency Getty Images Inc from private equity firm Hellman& Friedman LLC.

  • BRIEF-Watson gets approval from European commission to buy Actavis

    Oct 5- Watson Pharmaceuticals Inc:. *Receives approval from European commission for pending actavis acquisition. *Says transaction remains subject to regulatory approval in the United States.

  • Watson's buy of Swiss Actavis approved in EU

    BRUSSELS, Oct 5- U.S. drugmaker Watson Pharmaceuticals Inc secured EU regulatory clearance on Friday to buy Swiss peer Actavis Group for at least 4.25 billion euros to reinforce its international reach. It forecast synergies of more than $300 million within three years. The European Commission said in a statement that the deal would not hurt competition.

  • EU mergers and takeovers (Oct 5)

    BRUSSELS, Oct 5- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firms Carlyle and BC Partners to acquire U.S. industrial pumps maker Hamilton Sundstrand Industrial which is owned by United Technologies Corp.

  • EU mergers and takeovers (Oct 4)

    BRUSSELS, Oct 4- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firms Carlyle and BC Partners to acquire U.S. industrial pumps maker Hamilton Sundstrand Industrial which is owned by United Technologies Corp.

  • EU mergers and takeovers (Oct 3)

    BRUSSELS, Oct 3- The following are mergers under review by the European Commission and a brief guide to the EU merger process:. --Private equity firms Carlyle and BC Partners to acquire U.S. industrial pumps maker Hamilton Sundstrand Industrial which is owned by United Technologies Corp.